UroGen Pharma Ltd. Other Comprehensive Income (Loss), Net of Tax
UroGen Pharma Ltd. (URGN) reported Other Comprehensive Income (Loss), Net of Tax of -$98.00 thousand for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-04.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2021-08-04
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax for the quarter ending 2021-06-30 was -$98.00K, a 121.83% decline year-over-year.
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax for the quarter ending 2021-03-31 was -$128.00K, a 465.71% decline year-over-year.
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax for the quarter ending 2020-12-31 was -$221.00K.
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax for the quarter ending 2020-09-30 was -$268.00K, a 1318.18% decline year-over-year.
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax for fiscal 2020 was -$5.00K, a 101.81% decline from fiscal 2019.
- UroGen Pharma Ltd. other comprehensive income (loss), net of tax for fiscal 2019 was $276.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2021-06-30 | -$98.00K 10-Q · filed 2021-08-04 | -$226.00K 10-Q · filed 2021-08-04 | -$447.00K derived: sum of 3 quarters · filed 2021-08-04 | -$715.00K derived: sum of 4 quarters · filed 2021-08-04 |
| 2021-03-31 | -$128.00K 10-Q · filed 2021-05-13 | -$349.00K derived: sum of 2 quarters · filed 2021-05-13 | -$617.00K derived: sum of 3 quarters · filed 2021-05-13 | -$168.00K derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-12-31 | -$221.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$489.00K derived: sum of 2 quarters · filed 2021-03-18 | -$40.00K derived: sum of 3 quarters · filed 2021-08-04 | -$5.00K 10-K · filed 2021-03-18 |
| 2020-09-30 | -$268.00K 10-Q · filed 2020-11-09 | $181.00K derived: sum of 2 quarters · filed 2021-08-04 | $216.00K 10-Q · filed 2020-11-09 | $189.00K derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-06-30 | $449.00K 10-Q · filed 2021-08-04 | $484.00K 10-Q · filed 2021-08-04 | $457.00K derived: sum of 3 quarters · filed 2021-08-04 | $479.00K derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $35.00K 10-Q · filed 2021-05-13 | $8.00K derived: sum of 2 quarters · filed 2021-05-13 | $30.00K derived: sum of 3 quarters · filed 2021-05-13 | $311.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$5.00K derived: sum of 2 quarters · filed 2021-03-18 | $276.00K derived: sum of 3 quarters · filed 2021-03-18 | $276.00K 10-K · filed 2021-03-18 |
| 2019-09-30 | $22.00K 10-Q · filed 2020-11-09 | $303.00K derived: sum of 2 quarters · filed 2020-11-09 | $303.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $281.00K 10-Q · filed 2020-08-10 | $281.00K 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |